People · Operator
Named in public records as an officer, director or promoter · active 2009–2016 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Blade Therapeutics, Inc. | — | Biotechnology | Series B | $77.0M | $475.5M | 2016 |
| Limerick Biopharma Inc | — | Pharmaceuticals | Series B | $52.8M | $16.3M | 2009 |
| Theraclone Sciences, Inc. | — | Biotechnology | Series A | $36.7M | $111.3M | 2013 |
Wendye Robbins at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Wendye Robbins on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Steven Gillis | 1 | 23 |
| Wende Hutton | 1 | 16 |
| Kristina Burow | 1 | 16 |
| Corey Goodman | 1 | 13 |
| Luke Evnin | 1 | 12 |
| Chad Waite | 1 | 11 |
| Cameron Wheeler | 1 | 9 |
| Steve Dow | 1 | 7 |
| Scott Minick | 1 | 7 |
| Christopher Mirabelli | 1 | 6 |
| Elaine Jones | 1 | 6 |
| William Greene | 1 | 6 |
| Clifford Stocks | 1 | 5 |
| Stephen Dow | 1 | 4 |
| Corey S. Goodman | 1 | 4 |
| James Scopa | 1 | 3 |
| William Slattery | 1 | 2 |
| Kristine Swiderek | 1 | 2 |
| Russ Hawkinson | 1 | 2 |
| Peter Van Vlasselaer | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.